Stockscreener 앱 받기
3.21
1.23%
-0.04
시간 외 거래:
3.28
0.07
+2.18%
전일 마감가:
$3.25
열려 있는:
$3.275
하루 거래량:
1,923
Relative Volume:
0.02
시가총액:
$58.18M
수익:
-
순이익/손실:
-
주가수익비율:
-4.5262
EPS:
-0.7092
순현금흐름:
-
1주 성능:
+4.90%
1개월 성능:
-6.14%
6개월 성능:
-22.65%
1년 성능:
-19.55%
1일 변동 폭
$3.21
$3.28
1주일 범위
$3.04
$3.3199
52주 변동 폭
$2.5209
$7.00
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
ATHE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
3.21 | 58.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Sees Significant Drop in Short Interest - Defense World
CaixaBank (OTCMKTS:CAIXY) Hits New 52-Week High – Still a Buy? - Defense World
ProShares Short S&P 500 (NYSEARCA:SH) Sets New 1-Year Low – Here’s Why - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Alterity Therapeutics Ltd (ADR) trading halted, news pending - MSN
Insights: Alterity Therapeutics Ltd (ASX:ATH) - smallcaps.com.au
Antalpha Platform Holding Company (NASDAQ:ANTA) Short Interest Update - Defense World
Contrasting Alterity Therapeutics (NASDAQ:ATHE) & BioHarvest Sciences (NASDAQ:BHST) - Defense World
CapEx per share of Alterity Therapeutics Ltd. Sponsored ADR – NASDAQ:ATHE - TradingView
Alterity Therapeutics stock rises after positive MSA trial data presented at conference - Investing.com
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Finviz
Alterity Therapeutics (NASDAQ:ATHE) Shares Down 0.5% – What’s Next? - Defense World
Alterity Therapeutics presents ATH434-201 Phase 2 data - TipRanks
ASX recovers to shed just 0.13pc as healthcare and gold drags - Geelong Advertiser
Alterity Therapeutics raises A$20M in strategic placement - MSN
ATHE: A Tale of Ups & Downs – 63.16% gain in 6 Months, 42.35% in 30 Days - investchronicle.com
SMCI’s Market Flip-Flop: Exploring the Volatility of 2025 Performance - investchronicle.com
Alterity CEO to provide corporate update on ATH434 development - Investing.com
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity shares new phase 2 data on MSA treatment - Investing.com India
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity secures funding to advance MSA drug development - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Most active stocks: US stocks with the highest trading volume today - Yahoo
symbol__ Stock Quote Price and Forecast - CNN
- SEC.gov
Biotech Stocks: Longevity Company Stocks - Investing.com
Alterity Therapeutics LtdADR (ATHE) News, Articles, Events & Latest Updates - Stocktwits
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology - Investing.com India
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Ernexa Therapeutics (ERNA) Short Interest Ratio and Volume 2025 - MarketBeat
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy - Barchart.com
Trading Halts Explained - MarketBeat
Biggest Stock LosersToday’s Biggest Percentage Decliners - MarketBeat
IM Cannabis (IMCC) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Purple Biotech (PPBT) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
ATHE Financial Statements & ChartsAlterity Therapeutics LtdAdr MacroTrends - CMLviz
ATHE Pivot Points, Technical Analysis and Moving AveragesAlterity Therapeutics LtdAdr Technicals - CMLviz
Check up: A good fortnight to be a small cap health investor - Stockhead
Genprex (GNPX) Short Interest Ratio and Volume 2025 - MarketBeat
Integrated BioPharma (INBP) Short Interest Ratio and Volume 2025 - MarketBeat
ESSA Pharma (EPIX) Short Interest Ratio and Volume 2025 - MarketBeat
Immuron (IMRN) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Check up: Maybe next week will be better? - Stockhead
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Check up: Pot, takeovers, and COVID-19 are making investors happy - Stockhead
Maxim Group Analyst Recommendations & Stock Picks - MarketBeat
ATHE Stock Price | Alterity Therapeutics Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
ATH Stock Price and Chart — ASX:ATH - TradingView — Track All Markets
알테리티 테라퓨틱스 (ATHE) 재무 분석
알테리티 테라퓨틱스 (ATHE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):